Neumo­ra, Rayze­Bio look to each raise $200M+ in IPOs

Two biotech com­pa­nies, Neumo­ra and Rayze­Bio, hashed out their IPO plans Mon­day morn­ing, de­tail­ing hopes to raise around $227 mil­lion and $206 mil­lion, re­spec­tive­ly, in their Nas­daq de­buts.

The com­pa­nies could en­ter the pub­lic mar­ket as soon as this week. Both aim to price their shares be­tween $16 and $18. Neumo­ra, a neu­ro­science start­up, plans to of­fer 14.7 mil­lion shares of com­mon stock un­der the tick­er “NM­RA,” while ra­dio­phar­ma­ceu­ti­cals de­vel­op­er Rayze­Bio plans to list as “RYZB” and of­fer 13.2 mil­lion shares of com­mon stock.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER